All News
The complexity of opioid use in spondyloarthritis
A few things we know about opioids: use is common; it’s not efficacious in the treatment of spondyloarthritis; and, there is an opioid epidemic and its users are stigmatized. Abstract 0402 is a retrospective study that looked at patients with psoriatic arthritis or ankylosing spondylitis in the FORWARD databank. It sheds new light and leaves us with some food for thought
Read Article
ACR22: Polymyalgia Rheumatica in the Spotlight
One of the enduring legacies of ACR 2022 for me will be the emphasis on polymyalgia rheumatica (PMR). Despite being highly inflammatory and relatively common, a remarkable paucity of trials have been run in this space. Read on for a quick PMR-roundup from the meeting!
Read Article
@rheumecraig @RheumNow Absolutely. In this #ACR22 study, they did exclude anyone with deranged LFTs from this study and yet still two people in the turmeric arm got LFT derangement (vs zero in placebo). Sadly I don't think the turmeric salespeople are watching the LFTs.
David Liew drdavidliew ( View Tweet)
Abstr #2191 studies impact of maternal SLE on outcomes of children
Maternal SLE assoc w/ ↑ odds of
- SLE of children (HR 98.48, 95%CI:63.39-152.98)
- other AutoImm dx (HR 1.26, 1.02-1.57) (Hashimoto, JRA, IBD)
- Neurodev dx (1.35, 95%CI:1.15-1.57) (ADHD)
@RheumNow #ACR22
Akhil Sood MD AkhilSoodMD ( View Tweet)
UPA tx in prior TNFi tx PsA pts demonstrated consistent efficacy compared to the overall population in SELECT-PsA 2, regardless of number of prior anti-TNF therapies. Abs 2146 #ACR22 @RheumNow https://t.co/xnN4nvZ934 https://t.co/3S6ZzPvqVe
Dr. Rachel Tate uptoTate ( View Tweet)
How to adjust for GC correction when dose >/= 7.5mg/d using FRAX?
Calculate FRAX then
🦴For MOF risk multiply by 1.15
🦴HF risk multiply by 1.2
= adjusted risk (%)
(Adjustment of FRAX accdg to GC dose from Kanis et al., OI 2011)
#ACR22 @RheumNow @Rheumarhyme @PhRheumaJr https://t.co/qap1fFhF0h
sheila RHEUMarampa ( View Tweet)
What happens to #Sjogrens tests over time? Well nothing- serology and tests are stable over time for NIH in >2800 Pts from 1984-2020 in well characterized Pts. Abst#2025 #ACR22 @RheumNow I was surprised as I thought there would be worsening but if prevalent Pts already fibrotic?
Janet Pope Janetbirdope ( View Tweet)
Wheeler et al. MUC5B assoc risk RA-ILD, OR 2.25. No significant additive interaction with race, smoking, disease activity @RheumNow #ACR22 Abstr#2250 https://t.co/Hw2oBawKsd https://t.co/DqCQIPpEyg
Richard Conway RichardPAConway ( View Tweet)
Abstr #2195 COVID PrEP in Rheum pts who did not seroconvert after 3rd dose
- anti-SARS-CoV2 IgG levels ↑ after day 1
- Saliva IgG also ↑ up to day 14
- one reported COVID+ w mild symptoms
@RheumNow #ACR22 https://t.co/um2JFNMhpj
Akhil Sood MD AkhilSoodMD ( View Tweet)
Zuo @RayZuoMD @jasonsknight et al. High levels of anti-NET antibodies in 45% of aPL-positive patients May activate the complement cascade and contribute to brain white matter changes. @RheumNow #ACR22 Abstr#2269 https://t.co/JrjNvQRDim https://t.co/c4yXHLOmBJ
Richard Conway RichardPAConway ( View Tweet)
ILD in #scleroderma. #Scleroderma lung study III - NO DIFF between MMF + Pirfenidone vs MMF alone. Planned for 150 Pts but only 51 enrolled but p=0.9. A trial recruited during #COVID so difficult to enroll Abst#530 @RheumNow #ACR22 https://t.co/CBYEJ2YCVM
Janet Pope Janetbirdope ( View Tweet)
How does #COVID19 impact pregnant women with rheumatic disease? Does vaccination status make a difference? @RheumNow #ACR22
https://t.co/2oJ1RAeciN https://t.co/c9s6QRSOR4
Catherine Sims, MD DrCassySims ( View Tweet)
Baker et al. Optum database study. Tofa assoc reduced incident RA-ILD. aHR 0.33 (vs ADA) @RheumNow #ACR22 Abstr#2251 #ACRbest https://t.co/R5rQ3KcHnq https://t.co/8Nq0t4zqQK
Richard Conway RichardPAConway ( View Tweet)
#Vasculitis #ACR22 highlights. #Rituximab more remission in clinical care for GPA - observational, less infections if 600 mg IV fixed q6 mo how long to continue? Abst#1084 and less flares w Rituximab maintenance in the MAINRITSAN studies abst#527 Ritux is new SoC in GPA @RheumNow
Janet Pope Janetbirdope ( View Tweet)
Aggarwal @docrota et al. ProDERM results on skin and QoL. Statistically significant improvements in CDASI (both activity and damage) and SF-36. @RheumNow #ACR22 Abstr#2239 https://t.co/vsnvYUla13
Richard Conway RichardPAConway ( View Tweet)
Let's review how GCs induce #Osteoporosis 👇(every Rheum should know this!)
💊GCs have bone cell specific effects on:
💠Osteoclasts ⬆️resorption, survival
💠Osteoblasts ⬇️🦴formation & prolif; ⬆️apoptosis
💠Osteocytes ⬆️apoptosis & skeletal fragility
#ACR22 @RheumNow @rheumarhyme https://t.co/n61OXkmRgr
sheila RHEUMarampa ( View Tweet)
Espinosa-Ortega et al. Effect of DM ab on damage (as per MDI) over time. Most damage in PM/Scl>seronegative>other abs @RheumNow #ACR22 Abstr#2241 https://t.co/g8xTRyw6NZ https://t.co/sR1tT2QmU3
Richard Conway RichardPAConway ( View Tweet)
BKZ resulted in clinically meaningful improvements in FACIT-Fatigue and pain (PtAAP) in approximately half of pts w/ active PsA who are bDMARD-naïve or TNFi-IR. Abs 2119 #ACR22 @RheumNow https://t.co/29gzmMZRlG https://t.co/qziqGNxQih
Dr. Rachel Tate uptoTate ( View Tweet)
After 1st TNFi, cycling/swapping strategies both acceptable in PsA w/ similar retention rates. Further studies needed to perform survival subgroup analysis regarding different extra-articular manifestations and PsA subtypes. Abs 2149 #ACR22 @RheumNow https://t.co/SRPhSiGeUI https://t.co/EYDULe52A3
Dr. Rachel Tate uptoTate ( View Tweet)
Luedders et al. Higher plasma MMP-7 and MMP-9 assoc development incident RA-ILD in RA patients @RheumNow #ACR22 Abstr#2252 https://t.co/woVErubytC https://t.co/r916r1AxtN
Richard Conway RichardPAConway ( View Tweet)